Recently, the PD-1 checkpoint inhibitor pembrolizumab gained accelerated approval for treatment of patients with recurrent or metastatic cervical cancers expressing programmed death ligand 1 (PD-L1).8 PD-L1 is now established as a predictive marker for immunotherapy, although overall response rates are as low as 14.3% for PD-L1-positive cervical cancer patients.8 Other PD-1 inhibitors, such as Nivolumab, are currently being tested in clinical trials (ClinicalTrials.gov identifier: NCT02488759)9 and results are pending. Here, CD274 is linked to cervical carcinoma.